



CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A method for inhibiting replication of an RNA virus comprising contacting said RNA virus with a replication-inhibiting amount of a compound having the formula:



Compound I or



Compound II

2. (Original) A method according to claim 1, wherein said RNA virus is a flavivirus.
3. (Original) A method according to claim 2, wherein said flavivirus is hepatitis C virus (HCV) or bovine diarrhea virus (BVDV).
4. (Original) A method according to claim 1, wherein said contacting occurs *in vivo*.
5. (Original) A method according to claim 1, wherein said contacting occurs in a glutathione rich cell or tissue.
6. (Original) A method according to claim 5, wherein said cell or tissue is liver, kidney or gastrointestinal tract tissue.


7. (Original) A method according to claim 1, wherein said compound (I) or (II) is associated with a targeting agent.

8. (Original) A method according to claim 1, wherein said compound further comprises a glycoside.


9. (Original) A method according to claim 1, wherein a derivative of said compound is a metabolite of compound (I) or (II).

10. (Original) A method according to claim 9, wherein said metabolite of compound (I) or (II) is 6-mercaptopurine.

11. (Original) A method for inhibiting replication of an RNA virus in a host comprising administering to a host in need thereof a pharmaceutical composition including a therapeutically effective amount of a compound having the formula:



Compound I or



Compound II

12. (Original) A method according to claim 11, wherein said RNA virus is a flavivirus.

13. (Original) A method according to claim 12, wherein said flavivirus is hepatitis C virus (HCV).

14. (Original) A method according to claim 11, wherein compound (I) or (II) is associated with a targeting agent.

15. (Original) A method according to claim 11, wherein said host is a liver transplant patient.

16. (Original) A method according to claim 11, wherein said compound further comprises a glycoside.

17. (Original) A method according to claim 11, wherein a derivative of said compound is a metabolite of compound (I) or (II).

18. (Original) A method according to claim 17, wherein said metabolite of compound (I) or (II) is 6-mercaptopurine.

19. (Original) A method according to claim 17, wherein said derivative possessing antiviral activity is associated with a targeting agent capable of targeting said derivative to a pre-selected cell or tissue.

20. (Original) A method according to claim 19 wherein said pre-selected cell or tissue is lung tissue.